ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
FGF13 Deficiency Ameliorates Paclitaxel-Induced Neuropathic Pain by Inhibiting VASH1-Mediated Microtubule Detyrosination to Promote Mitophagy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mitochondrial damage in dorsal root ganglion (DRG) neurons contributes to the pathogenesis of paclitaxel (PTX)-induced peripheral neuropathic pain (PIPNP). Fibroblast growth factor 13 (FGF13), abundantly expressed in DRG neurons, is crucial for the regulation of somatosensation; however, its role in PIPNP remains unclear. Here, we demonstrated that FGF13 expression is upregulated in DRG neurons of PIPNP model mice. Conditional knockout of Fgf13 in DRG neurons effectively alleviates PTX-induced mitochondrial damage and neuropathic pain. RNA sequencing analysis revealed that mitophagy mediates the regulatory effects of FGF13 in PIPNP. Mechanistically, FGF13 physically interacts with vasohibin 1 (VASH1), regulating the binding of VASH1 to microtubules and promoting microtubule detyrosination. FGF13 ablation disrupts assembly of the FGF13-VASH1-α-tubulin ternary complex, impairing VASH1-mediated microtubule detyrosination and increasing microtubule tyrosination. The resulting accumulation of tyrosinated microtubules facilitates kinesin-3 (KIF1A)-driven lysosomal trafficking, which in turn promotes mitophagy activation and ultimately ameliorates PTX-induced mitochondrial damage and PIPNP. Furthermore, VASH1 overexpression in DRG neurons reversed the alleviating effects of FGF13 deficiency on PTX-induced mitochondrial damage and PIPNP. In summary, our findings demonstrate that FGF13 deficiency alleviates mitochondrial dysfunction and PIPNP by suppressing VASH1-dependent microtubule detyrosination and subsequently activating mitophagy. Targeting FGF13 may be a promising therapeutic strategy for PIPNP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.